Optimizing Outcomes in the Management of Multidrug-Resistant Gram-Negative Bacterial infections
This activity equips clinicians to diagnose and manage MDR gram-negative infections using real-world cases, rapid diagnostics, and evidence-based antimicrobial selection across acute care settings.
Target Audience
This activity is designed for an audience of Physicians.
Learning Objectives
- Demonstrate how to incorporate rapid and molecular diagnostic results into early treatment decisions for multidrug-resistant Gram-negative bacterial (MDR-GN) infections. Differentiate NPC from primary psychiatric and neurodevelopmental disorders
- Apply case-based algorithms to select targeted therapy based on diagnostic outcomes
- Explain the impact of rapid diagnostic turnaround time and accuracy on antimicrobial prescribing and stewardship outcomes
- Identify scenarios where rapid diagnostics can prevent unnecessary broad-spectrum antibiotic use
- Calculate AUC and Cmax for selected antimicrobials using clinical case data
- Adjust dosing regimens based on PK parameter interpretation to optimize efficacy and safety
- Apply PK/PD principles to tailor antibiotic dosing strategies according to bacterial strain, infection site, and patient immune status in order to optimize clinical outcomes
- Describe PK/PD targets relevant to different antibiotic classes and their role in maximizing treatment success
- Select optimal dosing strategies using PK/PD targets for MDR-GN infections in simulated cases
- Adjust antimicrobial regimens for elderly, obese, and organ-impaired patients using PK/PD principles
Commercial Support
This activity is supported from an independent medical education grant from Pfizer.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Matteo Bassetti MD, PhD (faculty) | N/A | Nothing to disclose |
Erin K. McCreary PharmD, BCIDP, FIDSA (faculty) | Advisor, Speaker | GSK |
Julian de la Torre-Cisneros MD, PhD (faculty) | Researcher | MSD, Advanz, Qiagen, Takeda |
Speaker | MSD, Shionogi, Pfizer, Menarini, Advanz, Qiagen, Takeda | |
Dorothy Caputo, MA, BSN, RN - President | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Orakle LLC Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance

Facebook
X
LinkedIn
Forward